|
|
|
|
| LEADER |
00000cam a2200000Ii 4500 |
| 001 |
SCIDIR_ocn993254670 |
| 003 |
OCoLC |
| 005 |
20231120010207.0 |
| 006 |
m o d |
| 007 |
cr cnu|||unuuu |
| 008 |
170710s2017 enka ob 001 0 eng d |
| 010 |
|
|
|a 2017946970
|
| 040 |
|
|
|a N$T
|b eng
|e rda
|e pn
|c N$T
|d N$T
|d OPELS
|d IDEBK
|d EBLCP
|d MERER
|d OCLCF
|d YDX
|d OCLCQ
|d UPM
|d OCLCQ
|d IDB
|d CASUM
|d OCLCO
|d OCLCQ
|d D6H
|d NJR
|d OCLCO
|d U3W
|d OCLCO
|d OCLCQ
|d MERUC
|d UKMGB
|d OCLCQ
|d WYU
|d OCLCO
|d OCLCA
|d TKN
|d OCLCQ
|d S2H
|d OCLCO
|d VT2
|d OCLCO
|d OCLCQ
|d SFB
|d OCLCO
|
| 016 |
7 |
|
|a 101713266
|2 DNLM
|
| 016 |
7 |
|
|a 018426045
|2 Uk
|
| 019 |
|
|
|a 993548392
|a 1007058403
|a 1011183842
|a 1066586302
|a 1235833067
|
| 020 |
|
|
|a 9780128124406
|q (electronic bk.)
|
| 020 |
|
|
|a 0128124407
|q (electronic bk.)
|
| 020 |
|
|
|z 9780128124390
|
| 020 |
|
|
|z 0128124393
|
| 035 |
|
|
|a (OCoLC)993254670
|z (OCoLC)993548392
|z (OCoLC)1007058403
|z (OCoLC)1011183842
|z (OCoLC)1066586302
|z (OCoLC)1235833067
|
| 050 |
|
4 |
|a RM171.5
|
| 060 |
|
4 |
|a 2017 H-025
|
| 060 |
|
4 |
|a WH 11.1
|
| 072 |
|
7 |
|a HEA
|x 039000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 014000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 022000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 112000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 045000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 616.1506
|2 23
|
| 100 |
1 |
|
|a Hedner, U.
|q (Ulla),
|e author.
|
| 245 |
1 |
0 |
|a Treating life-threatening bleedings :
|b development of recombinant coagulation factor VIIa /
|c Ulla K.E. Hedner.
|
| 246 |
3 |
0 |
|a Development of recombinant coagulation factor VIIa
|
| 264 |
|
1 |
|a London :
|b Academic Press,
|c [2017]
|
| 300 |
|
|
|a 1 online resource :
|b illustrations
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 588 |
0 |
|
|a Online resource; title from PDF title page (EBSCO, viewed July 11, 2017).
|
| 505 |
0 |
|
|a Front Cover; Treating Life-Threatening Bleedings; Copyright Page; Contents; About the Author; Preface and Acknowledgments; 1. Classical Bleeding Disease (Hemophilia); 1.1 The History of Hemophilia; 1.2 The Treatment of Hemophilia; 1.2.1 Fraction 1-0; 1.2.2 The clinical use of Fraction 1-0; 1.2.3 Prophylaxis in severe hemophilia; References; 2. My Encounter With Hemophilia (1959-82); 2.1 The Coagulation Laboratory in Malm�o; 2.2 Hemophilia Patients With Inhibitors, and a Method to Stop Bleeding in These Patients; 2.3 Plasma FVIIa for Hemophilia Patients.
|
| 505 |
8 |
|
|a 2.4 Treatment for the First Patients With FVIIa2.5 Potential Development of FVIIa to Be Used in Hemophilia; References; 3. The First Years at Novo Nordisk; 3.1 Recruitment by Novo Nordisk, 1983; 3.2 Hematology at Novo Industri During the 1980s; 3.2.1 The history of heparin and Novo Industri; 3.2.2 The development of modified heparins; 3.2.3 The development of LMWH at Novo Industri; 3.2.4 Substances to dissolve clots (thrombi); 3.2.5 The introduction of FVII at Novo Industri; References; 4. The Development of Recombinant FVIIa (rFVIIa) (1985-88); 4.1 Background and Start.
|
| 505 |
8 |
|
|a 4.2 Work on Recombinant FVIIa4.2.1 The organization of the hemostasis group; 4.2.2 Production challenges; 4.2.3 The development of necessary assays; 4.2.4 Characterization of the rFVIIa molecule; 4.2.5 Effects and side effects: preclinical animal studies; 4.3 Treatment of the First Patient With rFVIIa, 1988; References; 5. The Further Use and Development of rFVIIa (1989-96); 5.1 The Prompt Use of rFVIIa; 5.2 rFVIIa as a "Compassionate Use" Product in the United States; 5.3 Plans for the Clinical Development of rFVIIa; 5.4 The Merger of Novo and Nordisk Gentofte 1989 and Its Consequences.
|
| 505 |
8 |
|
|a 5.5 The Development and Licensing of rFVIIa 1990-965.6 The Development of Production Capacity and the US License; 5.7 Blood Product Advisory Committee, 1996; 5.8 Some Final Reflections; References; 6. Legal Issues Regarding the Use of rFVIIa in Hemophilia Patients With Inhibitors; 6.1 "Orphan Drug Act"; 6.2 Patent Rights (Intellectual Property); References; 7. Treatment With rFVIIa in Malm�o (1996-99); 7.1 Part-Time Employment at the Coagulation Clinic in Malm�o (1996-90); 7.2 The Third "Key Patient"; 7.3 What Did This Patient Teach Us?; References; 8. The Launching and Uses of rFVIIa.
|
| 505 |
8 |
|
|a 8.1 The Launching of rFVIIa (1996-2000)8.2 rFVIIa for Use in Areas Other Than Hemophilia; 8.2.1 rFVIIa and platelet dysfunctions; 8.2.2 rFVIIa and liver diseases; 8.2.3 rFVIIa and patients with a normal coagulation system; 8.2.4 rFVIIa and trauma; 8.2.5 rFVIIa and patients with cerebral hemorrhages; References; 9. Mechanism of Action and Dosage; 9.1 Mechanism of Action; 9.2 Dosage; References; 10. The Continued Development of rFVIIa During the 2000s; 10.1 rFVIIa-Potential Long-term Effect; 10.1.1 The distribution in the blood of injected rFVIIa.
|
| 650 |
|
0 |
|a Blood coagulation factors.
|
| 650 |
|
0 |
|a Blood coagulation factor VIII.
|
| 650 |
|
0 |
|a Blood coagulation disorders
|x Treatment.
|
| 650 |
|
0 |
|a Hemophilia
|x Treatment.
|
| 650 |
0 |
2 |
|a 1900s
|
| 650 |
0 |
2 |
|a 2000s
|
| 650 |
1 |
2 |
|a Factor VIIa
|x history
|0 (DNLM)D015942Q000266
|
| 650 |
2 |
2 |
|a Blood Coagulation Disorders
|x drug therapy
|0 (DNLM)D001778Q000188
|
| 650 |
2 |
2 |
|a Recombinant Proteins
|x therapeutic use
|0 (DNLM)D011994Q000627
|
| 650 |
|
2 |
|a Blood Coagulation Factors
|0 (DNLM)D001779
|
| 650 |
|
2 |
|a Factor VIII
|0 (DNLM)D005169
|
| 650 |
|
6 |
|a Sang
|x Coagulation
|x Facteurs.
|0 (CaQQLa)201-0061678
|
| 650 |
|
6 |
|a Sang
|x Coagulation
|x Facteur VIII.
|0 (CaQQLa)201-0173238
|
| 650 |
|
6 |
|a Sang
|0 (CaQQLa)201-0016719
|x Troubles de la coagulation
|0 (CaQQLa)201-0016719
|x Traitement.
|0 (CaQQLa)201-0377521
|
| 650 |
|
6 |
|a H�emophilie
|0 (CaQQLa)201-0088658
|x Traitement.
|0 (CaQQLa)201-0377521
|
| 650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x General.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Clinical Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Diseases.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Evidence-Based Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Internal Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a Blood coagulation disorders
|x Treatment
|2 fast
|0 (OCoLC)fst00834701
|
| 650 |
|
7 |
|a Blood coagulation factor VIII
|2 fast
|0 (OCoLC)fst00834706
|
| 650 |
|
7 |
|a Blood coagulation factors
|2 fast
|0 (OCoLC)fst00834710
|
| 650 |
|
7 |
|a Hemophilia
|x Treatment
|2 fast
|0 (OCoLC)fst00955087
|
| 655 |
|
0 |
|a Electronic books.
|
| 655 |
|
4 |
|a Internet Resources.
|
| 776 |
0 |
8 |
|i Print version:
|a Hedner, U. (Ulla).
|t Treating life-threatening bleedings.
|d London : Academic Press, [2017]
|z 9780128124390
|z 0128124393
|w (OCoLC)974698989
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780128124390
|z Texto completo
|
